Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention | Phase |
|---|---|---|
|
Dermatomyositis |
Drug: Prednisone Drug: Methotrexate Drug: Etanercept |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Toward Improved Understanding of Pathogenesis and Treatment of Childhood Onset Dermatomyositis |
| Estimated Enrollment: | 75 |
| Study Start Date: | August 2002 |
| Study Completion Date: | August 2002 |
| Primary Completion Date: | August 2002 (Final data collection date for primary outcome measure) |
The mortality of JDMS is 3-39% with over 40% of patients demonstrating long-term disability. Current first line therapy is high-dose corticosteroids with the attendant significant drug-related toxicity. Over 30% of JDMS patients fail to respond adequately to steroids and require additional immunosuppression, none of which have been tested in prospective, randomized, controlled trials. The unique occlusive vasculopathy in JDMS is critical in the pathogenesis and predictive of prognosis but poorly understood. Elevated levels of tumor necrosis factor (TNF) alpha have been shown to be present in JDMS and are associated with a more severe and chronic course.
Seventy-five children with definite JDMS will be enrolled in a 24-month prospective, randomized, multicentered trial comparing 3 treatments: oral prednisone (P), combination of oral prednisone and methotrexate (P/MTX), and combination of oral prednisone and etanercept (P/E). Primary response measures will be muscle strength and mean duration of steroid therapy. Secondary response variables are disability in daily function and height and weight growth velocity (steroid toxicity measures). The combination of P/E will be tested and compared to both P alone and the combination of P/MTX after 3, 6, 12, 18, and 24 months of treatment. In addition, the combination of P/MTX will be compared to P alone after 3, 6, 12, 18, and 24 months of treatment. In pretreatment muscle biopsies, proangiogenic factors (such as vascular endothelial cell growth factor and basic fibroblast growth factor), angiostatic factors (such as angiostatin and endostatin), and vascular morphology (vessel number, width, length and area) will be quantified and tested for ability to predict muscle strength and functional ability 3, 6, 12, 18, and 24 months later.
Eligibility| Ages Eligible for Study: | 4 Years to 16 Years (Child) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion criteria at the time of enrollment:
- Definite or probable diagnosis of JDMS by the criteria of Bohan and Peter
- No prior systemic steroid treatment for JDMS
- If able to become pregnant (females) or impregnate (males) and are sexually active, then must have negative serum pregnancy test at baseline and be utilizing effective form of birth control
- Patient and/or parent or legal guardian must be willing to sign consent and assent forms
Exclusion criteria at the time of enrollment:
- History of chronic or recurrent infections sufficient to preclude the use of etanercept
- Prior treatment with specific TNF-blocking agents
- Demonstration of cutaneous or gastrointestinal (GI) ulceration at the time of diagnosis
- JDMS-related pulmonary disease at time of diagnosis (interstitial lung disease or aspiration pneumonia confirmed by radiograph)
- JDMS-related cardiomyopathy (echocardiogram confirmation)
- Any uncontrolled, clinically significant pre-existent systemic disease (hepatic, renal, neurological, endocrine, cardiac, gastrointestinal, or hematologic disease) within 24 weeks of start of study
- Known HIV, hepatitis B surface antigen not related to vaccination, or hepatitis C antibody positivity
- Pregnant or nursing female
- Any of the following laboratory abnormalities at baseline: platelet count < 100,000/cmm, total white cell count of < 3000 cells/cmm, neutrophils < 1000 cells/cmm, serum bilirubin > 2 times upper limit of normal, estimated creatinine clearance of < 90 mL/min/1.73 M2 BSA estimated by formula for males age 2 to <13 (0.55 X ht in cms/serum creatinine), age 13-18 (0.7 X ht in cms/serum creatinine) and females age 2-18 (0.55 X ht in cms/serum creatinine)
- Received live virus vaccination within 3 months prior to study entry (contraindication for MTX or etanercept therapy)
- Past or current substance abuse or psychiatric history that would interfere with ability to give informed consent or comply with study requirements or physician instructions
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00035958
| United States, Ohio | |
| Cincinnati Childrens Hospital Medical Center | |
| Cincinnati, Ohio, United States, 45229 | |
| Principal Investigator: | Daniel J. Lovell, MD, MPH | Children's Hospital Medical Center, Cincinnati |
More Information
| Responsible Party: | Daniel J. Lovell, MD, MPH, Cincinnati Children's Hospital Medical Center |
| ClinicalTrials.gov Identifier: | NCT00035958 History of Changes |
| Other Study ID Numbers: | P60AR047784 NIAMS-078 |
| Study First Received: | May 7, 2002 |
| Last Updated: | July 31, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Children's Hospital Medical Center, Cincinnati:
|
Juvenile Dermatomyositis Pediatric Randomized Clinical Trial Pediatric Rheumatology |
Additional relevant MeSH terms:
|
Dermatomyositis Polymyositis Myositis Muscular Diseases Musculoskeletal Diseases Neuromuscular Diseases Nervous System Diseases Connective Tissue Diseases Skin Diseases Methotrexate Etanercept Prednisone Abortifacient Agents, Nonsteroidal Abortifacient Agents Reproductive Control Agents |
Physiological Effects of Drugs Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Dermatologic Agents Enzyme Inhibitors Folic Acid Antagonists Immunosuppressive Agents Immunologic Factors Antirheumatic Agents Nucleic Acid Synthesis Inhibitors Anti-Inflammatory Agents Glucocorticoids Hormones |
ClinicalTrials.gov processed this record on September 27, 2016